

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 52802

Manuscript Type: REVIEW

Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer

Tafreshi BK *et al.* Targeting refractory TNBC

Narges K Tafreshi, David L Morse, Marie Catherine Lee

Abstract

Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2 protein. In comparison to other types of breast cancer, TNBC characterizes for its aggressive behavior, more prone to early recurrence and a disease with poor response to molecular target therapy. Although TNBC is identified in only 25%-30% of American breast cancer cases annually, these tumors continue to be a therapeutic challenge for clinicians for several reasons: tumor heterogeneity, limited and toxic systemic therapy options, and often

Match Overview

1	Crossref 14 words "Novel Immunotherapeutic Approaches to the Treatment of Cancer", Springer Science and Business Media LLC, 2016	1%
2	Internet 14 words crawled on 31-May-2010 www.cspo.org	1%
3	Internet 13 words crawled on 30-Nov-2019 erc.bioscientifica.com	1%



ALL

IMAGES

VIDEOS

12,500 Results

Any time ▾

Interfering MSN-NONO complex-activated CREB signaling ...

<https://advances.sciencemag.org/content/6/8/eaaw9960> ▾

Triple-negative breast cancer (TNBC) is life-threatening because of limited **therapies** and lack of **effective therapeutic targets**. Here, we found that moesin (MSN) ...

Recent therapeutic trends and promising targets in triple ...

<https://www.sciencedirect.com/science/article/pii/S0163725819300208>

Breast cancer accounts for 25% of all types of **cancer** in women, and **triple negative breast cancer (TNBC)** comprises around 15~20% of **breast cancers**. Conventional chemotherapy and radiation are the primary systemic **therapeutic** strategies; no other FDA-approved targeted therapies are yet available as for TNBC.

Cited by: 7

Author: Soo-Yeon Hwang, Seojeong Park, You...

Publish Year: 2019

Diagnosis and Therapy of Triple-Negative Breast Cancer ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570613>

Jun 14, 2019 · The course of **therapy** and the **therapeutic** options which are currently possible in the case of TNBC are shown and discussed using a fictional patient as an example: The premenopausal patient, aged 42 at initial diagnosis, has histologically confirmed, poorly differentiated, invasive **triple-negative breast cancer** without evidence of distant ...

Cited by: 2

Author: Andreas Schneeweiss, Carsten Denker...

Publish Year: 2019

Targeting Breast Cancer Stem Cells to Overcome Treatment ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225226>

Aug 30, 2018 · 3. **Breast Cancer Stem Cells (BCSCs)** It has been identified a small population of CSC within BC termed **Breast Cancer Stem Cells (BCSC)**. Although in recent years, BC treatment options have been increasing exponentially, the treatment resistance and different side effects increased the necessity to find new **therapy** treatments to overcome resistance in patients with ...

Cited by: 13

Author: Sònia Palomeras, Santiago Ruiz-Martí...

Publish Year: 2018



Narrowing the focus: Therapeutic cell surface targets for



ALL IMAGES VIDEOS

12,500 Results Any time

Targeted Therapies for Triple-Negative Breast Cancer ...

<https://www.sciencedirect.com/science/article/pii/S0165614715001704>

Acquisition of **resistance to targeted therapies** is a hurdle to overcome for effective **TNBC therapy**. **Triple-negative breast cancers (TNBCs)** constitute a heterogeneous subtype of **breast cancers** that have a poor clinical outcome.

Cited by: 145 **Author:** Murugan Kalimutho, Kate Parsons, Kate ...

Publish Year: 2015

Recent therapeutic trends and promising targets in triple ...

<https://www.sciencedirect.com/science/article/pii/S0163725819300208>

Breast cancer accounts for 25% of all types of **cancer** in women, and **triple negative breast cancer (TNBC)** comprises around 15~20% of **breast cancers**. **Conventional chemotherapy** and **radiation** are the primary **systemic therapeutic strategies**; no other **FDA-approved targeted therapies** are yet available as for TNBC.

Cited by: 7 **Author:** Soo-Yeon Hwang, Seojeong Park, Youngj...

Publish Year: 2019

Interfering MSN-NONO complex-activated CREB signaling ...

<https://advances.sciencemag.org/content/6/8/eaaw9960>